Inve India ▾
PIPIIND

PI Industries Q4 FY26 results (Jan–Mar 2026) and concall

Chemicals · Concall AI · Call held 20 May 2026

P I Industries reported a resilient Q4 and full year FY26, with consolidated revenue of ₹6,713.7 crores and 25% EBITDA margins, despite a challenging global and domestic agrochemical market. The pharma business showed strong 40% growth, and new products are increasingly contributing to exports. The company is strategically investing in new growth platforms like NCEs, biologicals, and electronic chemicals, though these require longer gestation periods and have impacted asset turns.

You’re reading a preview. Opening the full call uses 1 concall credit.

Sign in to use your monthly call allowance.

What they filed

Q4 FY26: revenue down 12.4%, net profit down 39.4% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26
Revenue2,221 1,901 1,787 1,900 1,872 −16%1,376 −28%1,565 −12%
EBITDA628 512 456 519 541 −14%302 −41%337 −26%
Net profit508 373 330 400 409 −19%311 −17%200 −39%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.